The fate of 168 New Jersey suits against the makers of hormone replacement drugs has been thrown into doubt with the summary dismissal of the first two of the cases slated for trial. Superior Court Judge Jamie Happas ruled the state Products Liability Act's rebuttable presumption of adequate labeling applied and the plaintiffs failed to surmount it. She also dismissed the other counts, violation of the New Jersey Consumer Fraud Act and common law claims of fraudulent and negligent misrepresentation.
July 15, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The fate of 168 New Jersey suits against the makers of hormone replacement drugs has been thrown into doubt with the summary dismissal of the first two of the cases slated for trial.
Superior Court Judge Jamie Happas, the designated judge for all N.J. cases alleging hormone replacement therapy (HRT) drugs caused breast cancer, ruled Friday that the state Products Liability Act’s rebuttable presumption of adequate labeling applied and that the plaintiffs failed to surmount it.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
A large and well-established Tampa company is seeking a contracts administrator to support the company's in-house attorney and manage a wide...
We are seeking an attorney to join our commercial finance practice in either our Stamford, Hartford or New Haven offices. Candidates should ...
We are seeking an attorney to join our corporate and transactional practice. Candidates should have a minimum of 8 years of general corporat...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
